An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole.
Phase of Trial: Phase IV
Latest Information Update: 02 Feb 2016
At a glance
- Drugs Esomeprazole (Primary)
- Indications Heartburn
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 04 Jan 2011 Additional location 'China' identified as reported by ClinicalTrials.gov.
- 04 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 08 Dec 2010 New trial record